CDE Approves Stone’s Major Change
Major changes to Stone have been approved by the CDE.
In June 2022, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) reviewed and approved changes regarding the company name and manufacturing address for four product types: polyester bottles for oral liquid medicines (Registration No. B20190008708), polyester bottles for topical liquid medicines (Registration No. B20190007921), high-density polyethylene (HDPE) bottles for topical liquid medicines (Registration No. B20190007907), and polypropylene spray pumps for liquid medicines (Registration No. B20190006141). Additionally, ownership of five product types holding “Registration Status A”—including HDPE bottles for oral liquid medicines (Registration No. B20190008709), which were approved in December 2021—was transferred to Guangdong Shitong Pharmaceutical Packaging Materials Co., Ltd.
With the acquisition of these five products holding “Registration Status A,” Stone Medical is now set to officially supply products and services to domestic pharmaceutical companies. This move will further unlock the production capacity of Shitong—now in its 16th year of operation—and complete the company’s transformation from a small-to-medium-sized enterprise into a large-scale enterprise.
